Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 5Terminated 3No longer available 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Suspensions × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡